Nurix Therapeutics legal chief sells 16,715 shares

The Chief Legal Officer exercised options for 5,786 shares at $8.72, with 105,465 options reported after the transaction.

Available on EDGAR 11/04/2026 - 05:03 PM EST Accepted by SEC EDGAR 11/04/2026 - 05:03 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring sold 16,715 shares of common stock in three transactions on November 2 and 3, 2026, under a previously adopted Rule 10b5-1 trading plan. On November 2, she exercised options for 5,786 shares at $8.72 per share; her reported option position afterward was 105,465. The November 2 sales were 9,527 shares at a weighted average $25.7392 per share and 1,075 shares at $26.7628; on November 3, she sold 6,113 shares at a weighted average $25.8329.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Ring Christine

Role Chief Legal Officer

Sold 16,715 shs ($432K)

Approx. gross sale proceeds $432K

Approx. exercise cost $50K

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F4	6,113	$25.8329	$158K
Exercise	Employee Stock Option (right to buy) F1, F5	5,786	$0.00	$0.00
Exercise	Common Stock F1	5,786	$8.72	$50K
Sale	Common Stock F1, F2	9,527	$25.7392	$245K
Sale	Common Stock F1, F3	1,075	$26.7628	$29K

Holdings After Transaction: Employee Stock Option (right to buy) — 105,465 contracts (Direct); Common Stock — 4,406 shares (Direct)

Footnotes (5)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
2. F2. Represents the weighted average sale price. The lowest price at which shares were sold was $25.56 and the highest price at which shares were sold was $26.08. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
3. F3. Represents the weighted average sale price. The lowest price at which shares were sold was $26.64 and the highest price at which shares were sold was $26.80. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
4. F4. Represents the weighted average sale price. The lowest price at which shares were sold was $25.70 and the highest price at which shares were sold was $25.99. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
5. F5. The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Shares sold: 16,715 shares Sale price for 9,527 shares: $25.7392 per share Sale price for 1,075 shares: $26.7628 per share +4 more

7 metrics

Shares sold 16,715 shares Three common-stock sales on November 2 and 3, 2026

Sale price for 9,527 shares $25.7392 per share Weighted average price on November 2, 2026

Sale price for 1,075 shares $26.7628 per share Weighted average price on November 2, 2026

Sale price for 6,113 shares $25.8329 per share Weighted average price on November 3, 2026

Options exercised 5,786 shares November 2, 2026

Option exercise price $8.72 per share Options exercised on November 2, 2026

Options after transaction 105,465 options Reported after the November 2, 2026 transaction

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Employee Stock Option (right to buy)

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price."

Employee Stock Option (right to buy) technical

"Employee Stock Option (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NRIX shares did Christine Ring sell?

Christine Ring sold 16,715 shares of Nurix common stock across three transactions on November 2 and November 3, 2026, under a previously adopted Rule 10b5-1 trading plan. On November 2, she sold 9,527 shares at a weighted average $25.7392 per share and 1,075 shares at $26.7628; on November 3, she sold 6,113 shares at $25.8329.

How many NRIX options did Christine Ring exercise?

Christine Ring exercised options for 5,786 shares on November 2, 2026, at $8.72 per share. Her reported option position after the transaction was 105,465.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ring Christine

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		M(1)		5,786	A	$8.72	21,121	D
Common Stock	11/02/2026		S(1)		9,527	D	$25.7392(2)	11,594	D
Common Stock	11/02/2026		S(1)		1,075	D	$26.7628(3)	10,519	D
Common Stock	11/03/2026		S(1)		6,113	D	$25.8329(4)	4,406	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$8.72	11/02/2026		M(1)			5,786	(5)	02/12/2034	Common Stock	5,786	$0	105,465	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $25.56 and the highest price at which shares were sold was $26.08. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Represents the weighted average sale price. The lowest price at which shares were sold was $26.64 and the highest price at which shares were sold was $26.80. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

4. Represents the weighted average sale price. The lowest price at which shares were sold was $25.70 and the highest price at which shares were sold was $25.99. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

5. The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)